CytoDyn Inc CYDY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYDY is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.15
- Day Range
- $0.15–0.15
- 52-Week Range
- $0.13–0.42
- Bid/Ask
- $0.15 / $0.15
- Market Cap
- $149.00 Mil
- Volume/Avg
- 40,489 / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- https://www.cytodyn.com
Comparables
Valuation
|
Metric
|
CYDY
|
VIR
|
CHRS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.71 | — |
Price/Sales | — | 28.39 | 0.79 |
Price/Cash Flow | — | — | — |
Price/Earnings
CYDY
VIR
CHRS
Financial Strength
|
Metric
|
CYDY
|
VIR
|
CHRS
|
|---|---|---|---|
Quick Ratio | 0.01 | 8.68 | 1.14 |
Current Ratio | 0.08 | 9.05 | 1.43 |
Interest Coverage | −7.55 | — | −4.88 |
Quick Ratio
CYDY
VIR
CHRS
Profitability
|
Metric
|
CYDY
|
VIR
|
CHRS
|
|---|---|---|---|
Return on Assets (Normalized) | −363.12% | −20.03% | −27.74% |
Return on Equity (Normalized) | — | −25.63% | — |
Return on Invested Capital (Normalized) | — | −28.31% | −32.60% |
Return on Assets
CYDY
VIR
CHRS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wjcnqzsk | Dwx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hzpscqr | Fynhvql | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zmmqzqdy | Hjqcl | $98.1 Bil | |
MRNA
| Moderna Inc | Jxxbyphxk | Vyzdx | $39.1 Bil | |
ARGX
| argenx SE ADR | Lfpgsqs | Tvsy | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Lsmjwdwsq | Krc | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jdlbnhtw | Ycydqc | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Knxwhvwc | Jmsrn | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jvkvjcnxw | Kdtphbr | $12.5 Bil | |
INCY
| Incyte Corp | Qhjbsgtzm | Chbcwr | $11.9 Bil |